Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03095118

Daratumumab in Treatment of PGNMID and C3 GN

Membranoproliferative Glomerulonephritis Clinical Trial

Official title:
Single-center Phase 2 Open-label Trial Evaluating Efficacy and Safety of Daratumumab in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immune Deposits and C3 Glomerulopathy Associated With Monoclonal Gammopathy

Clinical Trial Summary

This study is being done to see if daratumumab is safe and effective in the treatment of proliferative glomerulonephritis with monoclonal immune deposits (PGNMID) and C3 glomerulopathy associated with monoclonal gammopathy (C3GN). This is an inflammatory disease in the kidney due to the production of abnormal proteins. There are no known standard effective treatments for patients with PGNMID and C3GN secondary to monoclonal gammopathy. These diseases are caused by abnormal production of proteins (monoclonals) by abnormal clones. Daratumamb has been shown to be effective in treating patients with multiple myeloma a disease which also caused by over production of monoclonal proteins from abnormal clones. Everyone in this study will receive daratumumab.

Clinical Trial Description

This study is an open-label phase 2 trial of the safety and efficacy of daratumumab, in the treatment of PGNMID and C3GN associated with monoclonal gammopathy. Subjects will be screened at outpatient Nephrology Clinic visit appointments and interested qualified subjects will be consented and offered participation in this trial. Once consent has been obtained baseline values will be established and subjects will begin treatment and follow-up for the next 12 months. Daratumumab will be administered once weekly for 8 weeks and then once every 2 weeks for 8 additional doses. Patients will be followed for a total of 12 months (6 months after the last infusion). A final visit for evaluation and collection of lab samples will be conducted at the end of the study. ;

Study Design

Related Conditions & MeSH terms

  • Glomerulonephritis
  • Glomerulonephritis, Membranoproliferative
  • Membranoproliferative Glomerulonephritis
Clinical Trial Details
NCT number NCT03095118
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase Phase 2
Start date September 7, 2017
Completion date May 12, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05985122 - New Analytic Tools for aHUS and C3G Diagnosis N/A
Recruiting NCT04183101 - Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Phase 2
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Active, not recruiting NCT05067127 - Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Phase 3
Active, not recruiting NCT05809531 - An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Phase 3
Completed NCT02093533 - Eculizumab in Primary MPGN Phase 2
Completed NCT01221181 - Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy Phase 1
Not yet recruiting NCT03180723 - Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis Phase 3
Active, not recruiting NCT04572854 - Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Phase 2
Recruiting NCT05996731 - Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases N/A
Available NCT04729062 - C3G/Primary IC-MPGN EAP